CEO Blog

June 12, 2014

RUTHIGEN CLEARED TO INITIATE HUMAN CLINICAL TRIALS FOR RUT58-60 IN THE U.S.

SANTA ROSA, Calif. — (June 12, 2014) — Ruthigen, Inc., (NASDAQ: RTGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications, is pleased to announce today that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application without a clinical hold to begin human clinical testing of RUT58-60. Read More…

June 3, 2014

CEO’s Letter to Shareholders

On June 3, 2014, Ruthigen filed a letter to its shareholders on Form 8-K with the U.S. Security and Exchange Commission. Click here to view the letter

March 31, 2014

Ruthigen Corporate Presentation – March 2014